John Newman

Director of Specialty Pharmaceuticals Research for Oppenheimer & Co. Inc., John Newman is an adept leader with a strong background in both chemistry and biochemistry. John Newman studied both subjects extensively throughout his academic years and has been working in related fields since launching his career. Passionate about his profession, John Newman is an active member of many industry organizations.

John Newman attended Loyola University Chicago to acquire his Bachelor of Science in Chemistry. Once he completed his undergraduate studies, John Newman continued his studies at the University of Maryland, Baltimore County, where he pursued a Ph.D. in Biochemistry, conducting research at Howard Hughes Medical Institute. John Newman then completed a post-doctoral fellowship in business and biochemistry at the University of Wisconsin-Madison.

Upon fulfilling his academic aspirations, John Newman entered the workforce as an Associate Analyst for Merrill Lynch in New York. Applying his expertise in biochemistry, John Newman focused his skills on the burgeoning field of biotechnology, joining Merrill Lynch & Co., Inc.'s biotech research team. In this position, John Newman wrote company reports, collaborated with clients, and maintained models.

After three years with Merrill Lynch & Co., Inc., John Newman further developed his scientific acumen as a Senior Specialty Pharmaceuticals Analyst for Oppenheimer & Co. Inc. Demonstrating a keen ability to adapt rapidly to his new role, John Newman spearheaded the coverage of 12 companies within 6 months of joining the Oppenheimer team and currently acts as Director of Specialty Pharmaceuticals Research for Oppenheimer & Co. Inc. John Newman now deftly manages the coverage of 23 companies, publishing research and conducting marketing operations with corporate clients. John Newman is a member of the American Chemical Society and the New York Society of Security Analysts, Inc.